President & Chief Executive Officer
Sena Biswas, PhD, MBA Chief Executive Officer joined the BOD of Mimetogen in 2009, leading the structuring and negotiation of the company's transactions with Bausch & Lomb and Allergan plc.
Prior to joining Mimetogen as CEO, he was with the Corporate Development Group at Ora, where he focused on raising ophthalmology dedicated financing vehicles as well as executing licensing transactions and equity investments in ophthalmology companies. Previously, he was a Managing Director at VIMAC Milestone Medica, a biotechnology venture incubator which invested and managed early-stage companies.
He was the first employee and Founding President of Merrimack Pharmaceuticals which subsequently grew to a peak market capitalization of over $1.5B and successfully launched a cancer drug. Earlier in his career, held roles of Director of Business Development at Rhone-Poulenc Rorer executing over 100 licensing and M&A transactions, Principle at TL Ventures where he invested in the Series A rounds of Esperion, Adolor, ViroPharma, all of which became NASDAQ listed companies, and an Associate with the Healthcare Investment Banking team currently at JP Morgan, advising biopharmaceutical clients on M&A, equity, and debt financing transactions.
He holds a BA in Biology from Brandeis University, a PhD in Molecular and Cellular Biology from the University of Pennsylvania, an MBA from the Wharton School, and completed a postdoctoral fellowship in Molecular Immunology at Harvard Medical School.
Vice President Finance & Chief Financial Officer
François Mongrain has more than 20 years of financial experience centered on technology, growth-oriented businesses. During his 9 years in Entrepreneurial Services and Merger & Acquisition at Ernst & Young, he worked with several technology companies primarily active in the health care sector.
Following his Ernst & Young years, he became a founding partner of BridgeCapital Inc., a private consulting firm offering strategic and financial expertise to biotechnology companies. Through his years at E&Y and BridgeCapital, Mr. Mongrain played instrumental roles in more than 12 start-ups and participated in several IPO and private placements for young emerging companies.
Prior to Mimetogen, Mr. Mongrain co-founded Innodia, a biotech company focusing its R&D activity in developing novel drug for the treatment of diabetes and obesity. As Vice President Finance & CFO and then Chief Operating Officer, he successfully financed the Company’s research & development operations over a six-year period prior to orchestrating the sale of the Company to a publicly-listed Canadian biotechnology Company.
François received a Bachelor of Commerce degree from the Ecole des Hautes Etudes Commerciales (Montreal) and earned his Charted Accountant designation with Ernst & Young in 1993.See More »
Senior Director, Clinical Development
Karen Meerovitch has over 15 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. At Mimetogen, Dr. Meerovitch started as the Company’s Senior Scientist and now serves as Senior Director, overseeing all non-clinical and clinical development activities of MIM-D3.
Prior to joining Mimetogen, she was Group Leader for all preclinical activities at Avance Pharma (Laval, Quebec). Prior to that she was Senior Scientist at Shire Biochem (Laval, Quebec), where she was a key contributor in the discovery and research of several projects in oncology drug discovery programs in the area of angiogenesis, apoptosis, and vascular targeting. Dr. Meerovitch has held appointments as Adjunct Professor at McGill University in the Department of Biochemistry and is currently in the Department of Pharmacology and Therapeutics. She is author or co-author of over 20 publications and reviews.
Dr. Meerovitch holds a B.Sc. and PhD. from McGill University and an M.Sc. from the University of Alberta, all in Biochemistry. She also completed a post-doctoral fellow in the Department of Medicine at McGill University.Go »